Catalogue Search | MBRL
Search Results Heading
Explore the vast range of titles available.
MBRLSearchResults
-
DisciplineDiscipline
-
Is Peer ReviewedIs Peer Reviewed
-
Item TypeItem Type
-
SubjectSubject
-
YearFrom:-To:
-
More FiltersMore FiltersSourceLanguage
Done
Filters
Reset
2
result(s) for
"Teixeira-Pinto, Armando, PhD"
Sort by:
Transparency, trust and minimizing burden to increase recruitment and recruitment in trials: a systematic review
by
Gonzalez, Andrea Matus, BNtrSc
,
Natale, Patrizia, MSc (ClinEpi)
,
Ruospo, Marinella, PhD
in
Internal Medicine
2021
Highlights•The barriers and facilitators to trial participation from the patient perspectives are captured in the themes of ambiguity of context and benefit, lacking awareness of opportunity, wary of added burden, skepticism, fear and mistrust, building confidence, and social gains and belonging to the community. •Trials were perceived as an opportunity for some patients to access free and high-quality healthcare •Patients feared discrimination and inequities in accessing healthcare, particularly among patients from vulnerable ethnic minority groups, discouraged participation in trials.
Journal Article
Can we predict pneumococcal bacteremia in patients with severe community-acquired pneumonia?
by
Teixeira-Pinto, Armando
,
Basílio, Carla
,
Mergulhão, Paulo
in
Automation
,
Bacteremia
,
Bacteremia - epidemiology
2013
This study aimed to evaluate the role of biomarkers as markers of pneumococcal bacteremia in severe community-acquired pneumonia (SCAP).
A prospective, single-center, observational cohort study of 108 patients with SCAP admitted to the intensive care department of a university hospital in Portugal was conducted. Leucocytes, C-reactive protein (CRP), lactate, procalcitonin (PCT), d-dimer, brain natriuretic peptide (BNP), and cortisol were measured within 12 hours after the first antibiotic dose.
Fifteen patients (14%) had bacteremic pneumococcal pneumonia (BPP). They had significantly higher levels of median CRP (301 [interquartile range, or IQR], 230-350] mg/L vs 201 [IQR, 103-299] mg/L; P = .023), PCT (40 [IQR, 25-102] ng/mL vs 8 [IQR, 2-26] ng/mL; P < .001), BNP (568 [IQR, 478-2841] pg/mL vs 407 [IQR, 175-989] pg/mL; P = .027), and lactate (5.5 [IQR, 4.5-9.8] mmol/L vs 3.1 [IQR, 1.9-6.2] mmol/L; P = .009) than did patients without BPP. The discriminatory power evaluated by the area under the receiver operating characteristic curve (aROC) for PCT (aROC, 0.79) was superior to lactate (aROC, 0.71), BNP (aROC, 0.67), and CRP (aROC, 0.70). At a cutoff point of 17 ng/mL, PCT showed a sensitivity of 87%, a specificity of 67%, a positive predictive value of 30% and a negative predictive value of 97%, as a marker of pneumococcal bacteremia.
In this cohort, significantly higher PCT, BNP, lactate, and CRP levels were found in BPP, and PCT presented the best ability to identify pneumococcal bacteremia. A PCT serum level lower than 17 ng/mL could identify patients with SCAP unlikely to have pneumococcal bacteremia.
Journal Article